Jan Moritz Middeke

12PUBLICATIONS
82CO-AUTHORS
Medical mycologyRheumatology and arthritisPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Medical molecular engineering of nucleic acids and proteins
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (12)

|Oct 28, 2025
Differential prognostic impact of myelodysplasia-related gene mutations in a European cohort of 4978 intensively treated AML patients.

Marius Bill, Jan-Niklas Eckardt, Konstanze Döhner

|Jun 25, 2025
Ruxolitinib in Patients With Corticosteroid-Refractory or Corticosteroid-Dependent Chronic Graft-Versus-Host Disease: 3-Year Final Analysis of the Phase III REACH3 Study.

Robert Zeiser, Domenico Russo, Ron Ram

|May 08, 2025
Age-stratified machine learning identifies divergent prognostic significance of molecular alterations in AML.

Jan-Niklas Eckardt, Waldemar Hahn, Rhonda E Ries

|Sep 16, 2024
Single or Double Induction With 7 + 3 Containing Standard or High-Dose Daunorubicin for Newly Diagnosed AML: The Randomized DaunoDouble Trial by the Study Alliance Leukemia.

Christoph Röllig, Björn Steffen, Christoph Schliemann

|May 26, 2023
UBTF tandem duplications are rare but recurrent alterations in adult AML and associated with younger age, myelodysplasia, and inferior outcome.

Julia-Annabell Georgi, Sebastian Stasik, Jan-Niklas Eckardt

|Jan 24, 2023
Alterations of cohesin complex genes in acute myeloid leukemia: differential co-mutations, clinical presentation and impact on outcome.

Jan-Niklas Eckardt, Sebastian Stasik, Christoph Röllig

Pageof 2

Frequent Collaborators

9 joint publications

Johannes Schetelig

6 joint publications

Christoph Röllig

6 joint publications

Stefan W Krause

5 joint publications

Christoph Schliemann